Institutional investors purchased a net $1.4 million shares of SRPT during the quarter ended June 2015. This may signal that the smart money is gaining interest in this company as the 66.29% of shares outstanding that institutional investors hold is actually below the Biotechnology industry average.
Mutual fund holders
Largest Quarterly Institutional Transactions
Latest Institutional Activity
EMERALD ADVISERS, INC. Bought 613.6 Thousand shares of Sarepta Therapeutics Inc